603392 万泰生物
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入1,498,370-23.09%2,245,4035,510,78311,185,1895,750,329
减:营业总成本1,780,002-7.72%2,395,6213,878,7175,747,9093,404,115
    其中:营业成本695,51411.33%759,045873,2421,170,412817,711
               财务费用(11,342)-72.87%(58,068)(92,977)(61,612)5,195
               资产减值损失(16,894)59.56%(103,626)(459,733)(20,503)(29,841)
公允价值变动收益23,07673.03%36,70724,6579,97728
投资收益66,511-28.83%109,63698,89836,11311,225
    其中:对联营企业和合营企业的投资收益------------
营业利润(184,442)-169.74%93,8381,401,4515,596,0382,328,456
利润总额(191,856)-177.94%67,4811,393,3925,582,6912,324,145
减:所得税费用(17,965)-26.17%(41,614)146,887719,390244,931
净利润(173,891)-164.29%109,0951,246,5044,863,3012,079,214
减:非控股权益(469)-112.23%2,859(1,175)127,50657,747
股东净利润(173,422)-165.04%106,2351,247,6804,735,7952,021,468

市场价值指针
每股收益 (元) *-0.140-166.67%0.0800.9903.7902.300
每股派息 (元) *------0.3201.0000.200
每股净资产 (元) *9.556-2.69%9.69310.01513.6217.357
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容